Intellectual Property Encourages Collaboration, R&D in Developing Economies

The Biotechnology Industry Organization(BIO) unveiled a report on the role of intellectual property rights in encouraging upstream research and development as well as downstream commercialization of biotechnology at the 2012 BIO International Convention.

Scientific American to Host BIO International Convention Super Session to Release 4th Annual Worldview Report and Scorecard Highlighting Emerging Markets

The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."

International Patent Issues Highlighted at House Judiciary Committee Hearing: BIO Submits Biotech's Challenges


Ron Cohen, President and CEO, Acorda Therapeutics, Inc.

Dr. Cohen discusses the plight of today's emerging biotech companies, and how the federal government can best support innovation within the industry.

2012 Special 301 Report: Biotech's International IP Issues

BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission.

China Compulsory License Proposed Provisions Draw Reaction from BIO

BIO's members appreciate the recognition by the Chinese government that robust patent protections will incentivize an innovative biotechnology sector in China.  However, this can only be achieved with policies that ensure rare and narrow use of compulsory licenses only in extreme circumstances.

China Patent Enforcement Comments to USPTO

The importance of intellectual property protection is now understood in China.  However, it appears as though the IP laws are implemented and enforced in ways that benefit Chinese companies over foreign companies.  If China aims to be a leader in biotechnology it needs to understand that intellectual property protections are fundamental for creating an enabling environment for biotechnology.  In this regard, China has yet far to go.

International IP and Small Businesses: Novavax CEO Testifies on BIO's Behalf

Stanley C. Erck, President and CEO of Novavax testified at the USPTO on behalf of BIO to discuss the importance of IP protection internationally for small biotechnology companies.

Paraguay IP Section 306 Monitoring: BIO Comments

BIO urges the United States Trade Representative to continue to address the persistent deficiencies in patent protection and data protection regimes in Paraguay.  These deficiencies raise issues in respect to Paraguay's bilateral and international obligations and deny adequate and effective protection for the intellectual property rights of BIO's members.

BIO Commends Department of Commerce for Promoting Robust Intellectual Property Standards and Policies Abroad

BIO joined the Pharmaceutical Research and Manufacturers of America (PhRMA) in a letter commending Department of Commerce Secretary Gary Locke for his leadership in promoting robust intellectual property standards and policies. The letter commends the United States Patent Office (PTO) for their engagement at the World Intellectual Property Organization (WIPO) resisting calls to commence negotiations on ill-advised and harmful changes to the global patent system relating to "genetic resources" and "traditional knowledge."